ArticleJournal of immunology (Baltimore, Md. : 1950)2009
Intestinal T cell responses to gluten peptides are largely heterogeneous: implications for a peptide-based therapy in celiac disease.
Article in Journal of immunology (Baltimore, Md. : 1950), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 3 syntheses or guidelines pooled it, 174 citations in OpenAlex.
- Determination of gluten immunogenic peptides for the management of the treatment adherence of celiac disease: A systematic review.World journal of gastroenterology · 2021Pooled it
- Gliadin-Specific T-Cells Mobilized in the Peripheral Blood of Coeliac Patients by Short Oral Gluten Challenge: Clinical Applications.Nutrients · 2015Pooled it
- Guideline
- Antibodies to the wheat storage globulin Glo-3A in children before and at diagnosis of celiac disease.Journal of pediatric gastroenterology and nutrition · 2011Trial
- Comprehensive Insights into Plant-Derived Bioactive Peptides: Sources, Technological Strategies, and Health Implications.Molecules (Basel, Switzerland) · 2026Review
- Evaluation of alpha-gliadin celiac disease epitopes in some Aegilops species containing the D genome.BMC plant biology · 2026Article
- Detection of Gliadin-Activated CD4Journal of cellular and molecular medicine · 2025Article
- Proteomic Profiling of Celiac-Toxic Motifs and Allergens in Cereals Containing Gluten.Journal of proteome research · 2025Article
- Celiac Disease-Narrative Review on Progress in Celiac Disease.Foods (Basel, Switzerland) · 2025Review
- Evaluation of the Frequency of HLA-DQ2/DQ8 Genes Among Patients with Celiac Disease and Those on a Gluten-Free Diet.Foods (Basel, Switzerland) · 2025Article
- Putting gluten back on menu - Safety assessment of polyphenol-rich wheat varieties in Celiac Disease.EFSA journal. European Food Safety Authority · 2024Article
- IL-10-producing regulatory cells impact on celiac disease evolution.Clinical immunology (Orlando, Fla.) · 2024Article
- Advances in the Treatment of Autism Spectrum Disorder: Current and Promising Strategies.Current medicinal chemistry · 2024Review
- Characterizations of a neutralizing antibody broadly reactive to multiple gluten peptide:HLA-DQ2.5 complexes in the context of celiac disease.Nature communications · 2023Article
- Screening of Spore-Forming Bacteria with Probiotic Potential in Pristine Algerian Caves.Microbiology spectrum · 2022Article
- Dissection of the Genetic Architecture for Quantities of Gliadins Fractions in Wheat (Frontiers in plant science · 2022Article
- Analytical and functional approaches to assess the immunogenicity of gluten proteins.Frontiers in nutrition · 2022Review
- E40 glutenase detoxification capabilities of residual gluten immunogenic peptides inFrontiers in nutrition · 2022Article
- The Role of Exposomes in the Pathophysiology of Autoimmune Diseases I: Toxic Chemicals and Food.Pathophysiology : the official journal of the International Society for Pathophysiology · 2021Review
- The Gluten-Free Diet for Celiac Disease and Beyond.Nutrients · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 3 countries.
Funding
Abstract
The identification of gluten peptides eliciting intestinal T cell responses is crucial for the design of a peptide-based immunotherapy in celiac disease (CD). To date, several gluten peptides have been identified to be active in CD. In the present study, we investigated the recognition profile of gluten immunogenic peptides in adult HLA-DQ2(+) celiac patients. Polyclonal, gliadin-reactive T cell lines were generated from jejunal mucosa and assayed for both proliferation and IFN-gamma production in response to 21 peptides from wheat glutenins and alpha-, gamma-, and omega-gliadins. A magnitude analysis of the IFN-gamma responses was performed to assess the hierarchy of peptide potency. Remarkably, 12 of the 14 patients recognized a different array of peptides. All alpha-gliadin stimulatory peptides mapped the 57-89 N-terminal region, thus confirming the relevance of the known polyepitope 33-mer, although it was recognized by only 50% of the patients. By contrast, gamma-gliadin peptides were collectively recognized by the great majority (11 of 14, 78%) of CD volunteers. A 17-mer variant of 33-mer, QLQPFPQPQLPYPQPQP, containing only one copy of DQ2-alpha-I and DQ2-alpha-II epitopes, was as potent as 33-mer in stimulating intestinal T cell responses. A peptide from omega-gliadin, QPQQPFPQPQQPFPWQP, although structurally related to the alpha-gliadin 17-mer, is a distinct epitope and was active in 5 out of 14 patients. In conclusion, these results showed that there is a substantial heterogeneity in intestinal T cell responses to gluten and highlighted the relevance of gamma- and omega-gliadin peptides for CD pathogenesis. Our findings indicated that alpha-gliadin (57-73), gamma-gliadin (139-153), and omega-gliadin (102-118) are the most active gluten peptides in DQ2(+) celiac patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.